BsAbs targeting CD3 are designed to bypass the TCR–MHC interaction normally required for TCR activation by co-engaging CD3 molecules on the T cell and a tumor antigen expressed on the surface of cancer cells. The gene discussed is HLA-C; the disease is neoplasm.